Increasing use of GLP-1 and combined GIP/GLP-1 drugs in skin health and treatment, from immune and metabolism effects to patient care

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 agonists may have beneficial effects on skin conditions linked to obesity and inflammation.

• Evidence suggests potential clinical benefits of GLP-1RAs and dual GIP/GLP-1 agonists in treating psoriasis and hidradenitis suppurativa.
• These agents are associated with improvements in wound healing and have a generally favorable skin-related safety profile.
• Cutaneous adverse events, including injection site reactions and hypersensitivity, have been increasingly reported with these treatments.
• Current data on their effects in dermatology are largely observational and heterogeneous, particularly outside psoriasis and hidradenitis suppurativa.
• GLP-1RAs and dual GIP/GLP-1 agonists may represent a new class of systemic modulators relevant to inflammatory and aesthetic dermatology.

Simplified